RC
TBPH icon

Rangeley Capital’s Theravance Biopharma TBPH Stock Holding History

Rangeley Capital’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Sell
99,500
-3,500
-3% -$57.9K 1.55% 14
2026
Q1 		$1.67M Buy
+103,000
New +$1.82M 1.62% 21
2025
Q3 		– Sell
-33,729
Closed -$372K – 142
2025
Q2 		$372K Buy
+33,729
New +$328K 0.44% 38

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Rangeley Capital's TBPH Position: Q2 2026 in Review

Rangeley Capital reduced its Theravance Biopharma (TBPH) stake by 3.4% in Q2 2026, selling an estimated $57.9K and leaving 99,500 shares worth $1.69M. The position accounts for 1.55% of the portfolio, ranked #14.

Rangeley Capital first reported a position in TBPH in Q2 2025 and has held it in 3 quarters since. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Rangeley Capital held 99,500 shares of Theravance Biopharma worth $1.69M as of Q2 2026.
  • Rangeley Capital sold 3,500 Theravance Biopharma shares in Q2 2026, an estimated $57.9K.
  • Theravance Biopharma made up 1.55% of Rangeley Capital's portfolio in Q2 2026, its #14 holding.
  • Rangeley Capital first reported a position in Theravance Biopharma in Q2 2025 and has held it in 3 quarters since.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.